Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortImmunotherapy for many cancers — the world's top-selling medicine.PD-1 immunotherapy, often combined with ipilimumab.
Body systemCancerCancer
Drug classImmune checkpoint inhibitorsImmune checkpoint inhibitors
SupplyPrescription onlyWHO essential medicinePrescription only
Main usesMelanoma, Non-small cell lung cancer, Kidney, bladder, head and neck cancers, Triple-negative breast cancer, Cervical and endometrial cancerMelanoma, Lung cancer, Kidney cancer, Oesophageal and stomach cancer, Hodgkin lymphoma
How it worksTakes the brakes off your immune cells so they can find and kill cancer.Releases a brake on immune cells so they attack cancer.
Starts working——
Half-lifeAbout 22 daysAbout 25 days
Typical adult dose200 mg every 3 weeks or 400 mg every 6 weeks IV.240 mg every 2 weeks or 480 mg every 4 weeks IV.
FormsIV infusion, Subcutaneous injectionIV infusion, Subcutaneous injection
Common side effectsTiredness, Rash and itch, Diarrhoea, Underactive thyroidTiredness, Rash, Diarrhoea, Thyroid problems
Serious side effectsPneumonitis, Colitis, Hepatitis, Type 1 diabetes, Myocarditis, Adrenal or pituitary failurePneumonitis, Colitis, Hepatitis, Endocrine failure
Don't take if——
Alcohol——
PregnancyUsually avoidedContraception needed.Usually avoidedContraception needed.
Breastfeeding——
In use since20142014
Brand namesUnited States: Keytruda, Keytruda QlexUnited Kingdom: KeytrudaIndia: KeytrudaUnited States: Opdivo, Opdivo QvantigUnited Kingdom: OpdivoIndia: Opdyta, Opdivo
Legal status——
ATC codeL01FF02L01FF01

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker